Pharvaris (NASDAQ:PHVS) Sees Large Increase in Short Interest

Pharvaris (NASDAQ:PHVS) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 90,400 shares, a growth of 813.1% from the March 31st total of 9,900 shares. Currently, 0.9% of the shares of the stock are short sold. Based on an average trading volume of 102,500 shares, the short-interest ratio is presently 0.9 days.

Institutional Investors Weigh In On Pharvaris

Several hedge funds have recently modified their holdings of the company. Hudson Bay Capital Management LP bought a new position in Pharvaris in the 3rd quarter valued at approximately $812,000. Walleye Capital LLC lifted its holdings in shares of Pharvaris by 15.2% during the third quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock worth $1,691,000 after purchasing an additional 10,691 shares during the period. Blackstone Inc. acquired a new position in shares of Pharvaris during the fourth quarter worth $2,805,000. Vivo Capital LLC bought a new stake in shares of Pharvaris in the fourth quarter worth $7,994,000. Finally, Commodore Capital LP acquired a new stake in Pharvaris in the fourth quarter valued at $22,440,000.

Pharvaris Stock Up 7.2 %

Shares of PHVS stock traded up $1.52 on Thursday, reaching $22.77. The company had a trading volume of 82,367 shares, compared to its average volume of 102,201. The business’s 50-day moving average is $23.55 and its 200 day moving average is $23.32. Pharvaris has a one year low of $7.93 and a one year high of $33.00.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, April 10th. The company reported ($0.80) EPS for the quarter. As a group, equities research analysts anticipate that Pharvaris will post -2.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PHVS. Morgan Stanley reissued an “overweight” rating and set a $34.00 target price on shares of Pharvaris in a report on Monday. Wedbush restated an “outperform” rating and issued a $35.00 target price on shares of Pharvaris in a research report on Thursday, April 11th. Finally, JMP Securities boosted their price objective on shares of Pharvaris from $49.00 to $50.00 and gave the company a “market outperform” rating in a research report on Thursday, April 11th.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).